The German biotechnology company "Cure Fak" said today, Tuesday, that the Qatar Investment Authority purchased an undisclosed stake in the company, as part of a round of raising $ 126 million in financing before a possible listing on the stock.
Today's announcement is the fourth in two months of pumping and comes a day after British drug company GSK purchased a 10% stake for an investment of $ 171 million.
The German government also invested 343 million dollars in June, against a 23% stake in the company, bringing the total investment during the special financing round to about 640 million, according to "Cure Fak".
The company, backed by billionaire Bill Gates, also secured a loan of 75 million euros (85.79 million dollars) from the European Investment Bank earlier this month.
The company said it raised $ 126 million from the Qatar Investment Authority and a group of new and existing investors.
A spokesman refused to disclose the size of the Qatar Investment Authority or details of the stake size, and the Qatar Investment Authority declined to comment.
CureFac is a pioneer in the use of RNA to develop vaccines and monoclonal antibodies for infectious diseases.
US President Donald Trump sparked controversy last March with the announcement of the company's research progress to produce a vaccine for "Covid-19".
Trump offered the company huge funds at the time to ensure that the vaccine was obtained exclusively for the United States, which angered the German government, which responded that the company and German experts are not for sale.
"German researchers play a fundamental role in developing drugs and vaccines, and we cannot allow others to seek exclusive possession of their results," said Foreign Minister Haikou Maas at the time.
Informed sources told Reuters that "Cure Fak" plans to list its shares on the stock exchange in September or October.